UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
UroGen Pharma Ltd. (Nasdaq: URGN) will report its first quarter 2021 financial results on May 13, 2021, before market open. This will be followed by a live audio webcast at 8:30 AM ET. UroGen focuses on developing treatments for specialty cancers and urologic diseases, with its proprietary RTGel™ platform aiming to enhance the therapeutic profiles of existing drugs. UGN-102, their first commercial product for low-grade non-muscle invasive bladder cancer, offers a non-surgical treatment option.
- None.
- None.
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report first quarter 2021 financial results on Thursday, May 13, 2021, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.
Audio Webcast
The webcast will be made available on the Investors section of the Company’s website at http://investors.urogen.com. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
Dial-In Information
Live (U.S. / Canada): (855) 765-5685
Live (International): (615) 247-5916
Confirmation number: 5768352
About UroGen Pharma Ltd.
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005066/en/
FAQ
What date will UroGen Pharma report its Q1 2021 financial results?
What is UGN-102 developed by UroGen Pharma?
What technology does UroGen Pharma utilize for drug delivery?
When is the UroGen Pharma conference call scheduled?
